An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

NCT00561197 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Drug not being developed for this indication

Conditions

Locally Advanced Esophageal or GE Junction Cancer

Interventions

DRUG: AT-101

Sponsor

Ascenta Therapeutics